Pharmacologic Management of Chronic Obstructive Pulmonary Disease: A review of the literature
Main Article Content
Abstract
Chronic obstructive pulmonary disease (COPD) is a long-term lung illness that affects both the bronchioles and distal alveoli. COPD is an extremely common outpatient global condition, which carries an immense socio- economic burden that is only to increase over the subsequent years. While preventable and treatable, it remains a leading cause of death worldwide. Optimizing pharmacologic management is central to improving patient outcomes and quality of life, yet therapeutic decisions continue to evolve as evidence expands. This review synthesizes current literature and guideline recommendations on the pharmacologic management of stable COPD patients in the outpatient setting, encompassing the role of bronchodilators, inhaled corticosteroids, anti-inflammatory agents, phosphodiesterase inhibitors, and emerging biologics. In addition, we discuss the clinical relevance and evidence surrounding the use of suppressive antibiotics, systemic corticosteroids, mucolytics, and antileukotrienes as adjunctive therapies in selected patients. Evidence from pivotal trials supports dual bronchodilator therapy (long-acting muscarinic antagonists (LAMA)/ long-acting Beta-2 agonists (LABA)) as first-line treatment for most patients, with escalation to triple therapy (LAMA/LABA/inhaled Corticosteroids (ICS)) for those with persistent symptoms or exacerbations, particularly among individuals with higher blood eosinophil counts. Chronic macrolide use, roflumilast, and novel agents such as ensifentrine and dupilumab have further expanded the therapeutic landscape, targeting inflammation and exacerbation prevention in selected phenotypes. Collectively, current data emphasize a personalized, stepwise approach to COPD management, one guided by symptom burden, exacerbation risk, and biomarker profiling, while highlighting the need for continued research into precision therapies and optimal de-escalation strategies to balance efficacy, safety, and cost- effectiveness.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Lamprecht B, McBurnie MA, Vollmer WM, et al. COPD in never smokers: results from the population-based burden of obstructive lung disease study. Chest. Apr 2011;139(4):752-763. doi:10.1378/chest.10-1253
3. Khan KS, Jawaid S, Memon UA, et al. Management of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Hospitalized Patients From Admission to Discharge: A Comprehensive Review of Therapeutic Interventions. Cureus. Aug 2023;15(8):e43694. doi:10.7759/cureus.43694
4. Dixit D, Bridgeman MB, Andrews LB, et al. Acute exacerbations of chronic obstructive pulmonary disease: diagnosis, management, and prevention in critically ill patients. Pharmacotherapy. Jun 2015;35(6):631-48. doi:10.1002/phar.1599
5. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. Aug 25 2011;365(8):689-98. doi:10.1056/NEJMoa1104623
6. Martinez FJ, Curtis JL, Albert R. Role of macrolide therapy in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2008;3(3):331-50. doi:10.2147/copd.s681
7. Matzneller P, Krasniqi S, Kinzig M, et al. Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy. Antimicrob Agents Chemother. Apr 2013;57(4):1736-42. doi:10.1128/AAC.02011-12
8. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med. Nov 27 2008;359(22):2355-65. doi:10.1056/NEJMra0800353
9. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. Aug 29 2009;374(9691):695-703. doi:10.1016/S0140-6736(09)61252-6
10. US Food and Drug Administration Prescribing Information for Delirasp. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022522s009lbl.pdf
11. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. Feb 22 2007;356(8):775-89. doi:10.1056/NEJMoa063070
12. Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. Apr 30 2016;387(10030):1817-26. doi:10.1016/S0140-6736(16)30069-1
13. Vestbo J, Fabbri L, Papi A, et al. Inhaled corticosteroid containing combinations and mortality in COPD. Eur Respir J. Dec 2018;52(6) doi:10.1183/13993003.01230-2018
14. Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. Jun 15 2014;189(12):1503-8. doi:10.1164/rccm.201402-0207OC
15. Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. Dec 2014;44(6):1697-700. doi:10.1183/09031936.00162414
16. Varricchi G, Bagnasco D, Borriello F, Heffler E, Canonica GW. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs. Curr Opin Allergy Clin Immunol. Apr 2016;16(2):186-200. doi:10.1097/ACI.0000000000000251
17. Donovan T, Milan SJ, Wang R, Banchoff E, Bradley P, Crossingham I. Anti-IL-5 therapies for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. Dec 8 2020;12(12):CD013432. doi:10.1002/14651858.CD013432.pub2
18. Gandhi NA, Pirozzi G, Graham NMH. Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol. May 2017;13(5):425-437. doi:10.1080/1744666X.2017.1298443
19. Le Floc'h A, Allinne J, Nagashima K, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Ralpha antibody, is required to broadly inhibit type 2 inflammation. Allergy. May 2020;75(5):1188-1204. doi:10.1111/all.14151
20. Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med. Jun 27 2024;390(24):2274-2283. doi:10.1056/NEJMoa2401304
21. Lee JH, Kim HJ, Kim YH. The Effectiveness of Anti-leukotriene Agents in Patients with COPD: A Systemic Review and Meta-analysis. Lung. Aug 2015;193(4): 477-86. doi:10.1007/s00408-015-9743-5
22. Liu L, Wang JL, Xu XY, Feng M, Hou Y, Chen L. Leukotriene receptor antagonists do not improve lung function decline in COPD: a meta-analysis. Eur Rev Med Pharmacol Sci. Feb 2018;22(3):829-834. doi:10.26355/eurrev_201802_14319
23. Cazzola M, Calzetta L, Page C, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev. Sep 2015;24(137):451-61. doi:10.1183/16000617.00002215
24. Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. Jul 29 2015;(7):CD001287. doi:10.1002/14651858.CD001287.pub5
25. Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L. Efficacy and safety profile of mucolytic/antioxidant agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-acetylcysteine. Respir Res. May 27 2019;20(1):104. doi:10.1186/s12931-019-1078-y
26. Ni W, Shao X, Cai X, et al. Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis. PLoS One. 2015;10(3):e0121257. doi:10.1371/journal.pone.0121257
27. Herath SC, Normansell R, Maisey S, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. Oct 30 2018;10(10):CD009764. doi:10.1002/14651858.CD009764.pub3
28. Gartman EJ, Mulpuru SS, Mammen MJ, et al. Summary for Clinicians: Clinical Practice Guideline on Pharmacologic Management of Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. Jan 2021;18(1):11-16. doi:10.1513/AnnalsATS.202007-880CME
29. Anzueto A, Barjaktarevic IZ, Siler TM, et al. Ensifentrine, a Novel Phosphodiesterase 3 and 4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease: Randomized, Double-Blind, Placebo-controlled, Multicenter Phase III Trials (the ENHANCE Trials). Am J Respir Crit Care Med. Aug 15 2023;208(4):406-416. doi:10.1164/rccm.202306-0944OC
30. Rabe KF, Martinez FJ, Ferguson GT, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. N Engl J Med. Jul 2 2020;383(1):35-48. doi:10.1056/NEJMoa1916046
31. Muro S, Kawayama T, Sugiura H, et al. Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history. Respir Res. Aug 5 2024;25(1):297. doi:10.1186/s12931-024-02918-8
32. Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet. Mar 7 2015;385(9971):857-66. doi:10.1016/S0140-6736(14)62410-7
33. Sciurba FC, Criner GJ, Christenson SA, et al. Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype. N Engl J Med. May 1 2025;392(17):1710-1720. doi:10.1056/NEJMoa2413181
34. Singh D, Higham A, Mathioudakis AG, Beech A. Chronic Obstructive Pulmonary Disease (COPD): Developments in Pharmacological Treatments. Drugs. Jul 2025;85(7):911-930. doi:10.1007/s40265-025-02188-8